Stoke Therapeutics initiated with a Buy at Chardan

Chardan initiated coverage of Stoke Therapeutics (STOK) with a Buy rating and $24 price target The firm cites the potential of the company’s lead asset zorevunersen for the treatment of Dravet syndrome for the Buy rating. It believes STK-001 has demonstrated solid proof-of-concept with “robust” treatment effect and favorable safety in the Phase 1/2 studies. STK-001 could become the first disease modifying therapy approved for this rare epilepsy disease, for which Chardan models over $1B in peak sales, the analyst tells investors in a research note.